Literature DB >> 15686783

CD14 C(-260)T promoter polymorphism and prevalence of acute coronary syndromes.

Ramón Arroyo-Espliguero1, Khaled El-Sharnouby, Eugenia Vázquez-Rey, Kamini Kalidas, Steve Jeffery, Juan Carlos Kaski.   

Abstract

BACKGROUND: Inflammation and infection have been implicated in atherosclerosis and its complications. The CD14 receptor mediates monocyte activation by lipopolysaccharide (LPS) of Gram-negative bacteria. The aim of this study was to assess whether the C(-260)T polymorphism in the promoter of the CD14 receptor gene is associated with a higher prevalence of acute coronary syndromes (ACS) and severity of coronary atherosclerosis.
METHODS: We studied 428 patients (mean age: 63+/-10 years, 67% men) consisting of 334 patients with coronary artery disease (CAD) and 94 patients with normal coronary arteriogram. Patients with CAD were subdivided in two groups: (1) no previous history of ACS (n=140; 64+/-9 years; 79% men) and (2) patients with a history of ACS (n=194; 64+/-10 years; 80% men). CD14 genotypes were determined by a Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism Analysis (RFLP) technique.
RESULTS: Patients with a prior ACS had a significantly higher frequency of the T/T genotype than CAD patients without prior ACS (33% vs. 20%; P=0.009), even after multivariate analysis (odd ratio [OR] 1.8 [1.1-3.1]; confidence intervals [CI] 95%; P=0.023). T/T genotype was not significantly different in CAD patients without prior ACS compared to controls (20% vs. 22.3%; P=0.67), and there was no significant association between genotypes, or allele frequencies, and severity of CAD.
CONCLUSIONS: The CD14 C(-260)T polymorphism is associated with a history of ACS and it may represent a genetically determined risk factor for the development of ACS and atheromatous plaque vulnerability in angina patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686783     DOI: 10.1016/j.ijcard.2003.12.015

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  The association between CD14 gene C-260T polymorphism and coronary heart disease risk: a meta-analysis.

Authors:  Hong Pu; Jiong Yin; Yan Wu; Dongming Zhang; Yanian Wang; Rong Zhou; Lijuan Jiang; Yan Liu
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

2.  CD14 and IL6 polymorphisms are associated with a pro-atherogenic profile in young adults with acute myocardial infarction.

Authors:  Lidio Gonçalves Lima-Neto; Rosario Dominguez Crespo Hirata; André Ducati Luchessi; Vivian Nogueira Silbiger; Marco Antonio Stephano; Marcelo Ferraz Sampaio; Dikran Armaganijan; Mario Hiroyuki Hirata
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

3.  CD14 gene-159C/T polymorphism and coronary artery disease: a meta-analysis involving 4467 subjects.

Authors:  Yan-Yan Li; Xiang-Ming Wang; Chuan-Wei Zhou; Jian Xu; Yun Qian
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Investigating intestinal permeability and gut microbiota roles in acute coronary syndrome patients.

Authors:  Tarik Alhmoud; Anand Kumar; Chien-Chi Lo; Rana Al-Sadi; Stacey Clegg; Ihab Alomari; Tarek Zmeili; Cheryl Diane Gleasne; Kim Mcmurry; Armand Earl Ko Dichosa; Momchilo Vuyisich; Patrick Sam Guy Chain; Shiraz Mishra; Thomas Ma
Journal:  Hum Microb J       Date:  2019-07-19

5.  The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals.

Authors:  Reena Rajasuriar; Yong Yean Kong; Reshika Nadarajah; Noor Kamila Abdullah; Tim Spelman; Muhamad Yazli Yuhana; Sasheela Ponampalavanar; Adeeba Kamarulzaman; Sharon R Lewin
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

6.  Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy.

Authors:  Yean K Yong; Esaki M Shankar; Clare L V Westhorpe; Anna Maisa; Tim Spelman; Adeeba Kamarulzaman; Suzanne M Crowe; Sharon R Lewin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.